It was particularly noteworthy that SLC12A5 was positively associated with GABAA receptor activity and low expression of SLC12A5 shaped an immunosuppressive microenvironment in glioma indicating its predictive value for glioma immunotherapy. This evidence concerns the gene SLC12A5 and central nervous system cancer.